Amgen Inc. has been upgraded to a cautious Buy due to its improved fundamentals, diversified drug pipeline, and attractive risk/reward profile despite recent underperformance against the S&P 500. Key growth drivers include drugs like Imdelltra, Uplizna, Tepezza, Repatha, and the promising Maritide, which help offset declines from older drugs like Prolia. The company's strong R&D pipeline, margin expansion, and capital investments support long-term growth, though investors should monitor its high debt and capital expenditure levels. Amgen's shares currently trade near the lower end of a long-term range, with potential upside as defensive healthcare stocks gain favor amid changing market conditions.
The Schwab U.S. Dividend Equity ETF (SCHD) focuses on 100 stocks with strong dividend histories, offering retirees a reliable income with a 3.27% yield and low fees. However, its top 10 holdings make up 41% of the fund, exposing investors to higher s...
Amgen announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, featuring executives Peter Griffith and Murdo Gordon. The presentation will be webcast live and accessible to the public, investors, and me...
Quantinuum, formed by merging Honeywell's quantum division and Cambridge Quantum, debuted on Nasdaq at $68 per share, raising $1.68 billion in an upsized IPO. The company, valued at about $17.6 billion, offers full-stack quantum computing hardware an...
The European Commission has approved Amgen's IMDYLLTRA (tarlatamab) as a monotherapy for adults with advanced small-cell lung cancer (SCLC) after progression on platinum-based chemotherapy. This approval is based on the Phase 3 DeLLphi-304 trial show...
Amgen presented new Phase 3 data at the EULAR 2026 Congress showing that UPLIZNA (inebilizumab) provides sustained disease control and a strong safety profile in IgG4-related disease (IgG4-RD). No flares occurred in patients continuing UPLIZNA, with ...
